Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Anti-interleukin-6 therapy in rheumatoid arthritis
Robert Woodrick
,
Eric M. Ruderman
Medicine, Rheumatology Division
Research output
:
Contribution to journal
›
Article
›
peer-review
28
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Anti-interleukin-6 therapy in rheumatoid arthritis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Rheumatoid Arthritis
100%
Rheumatoid Arthritis Treatment
100%
Tocilizumab
100%
Anti-interleukin-6
100%
Monoclonal Antibody
50%
Pathophysiology
50%
Tumor Necrosis Factor-α
50%
Signal Process
50%
Disease Process
50%
Recent Advances
50%
Interleukin-6
50%
Randomized Controlled Trial
50%
Adverse Events
50%
New Therapeutic Agents
50%
Anti-TNF Therapy
50%
Biologic DMARDs
50%
IL-6 Receptor
50%
Medicine and Dentistry
Rheumatoid Arthritis
100%
Interleukin 6
100%
Inflammatory Arthritis
100%
Cytokine
75%
Tumor Necrosis Factor
50%
Tocilizumab
50%
Biological Product
25%
Receptor
25%
Adverse Event
25%
Therapeutic Agent
25%
Pathophysiology
25%
Disease Process
25%
Randomized Controlled Trial
25%
Disease-Modifying Antirheumatic Drug
25%
Monoclonal Antibody
25%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
100%
Interleukin 6
100%
Inflammatory Arthritis
100%
Cytokine
75%
Tumor Necrosis Factor
50%
Tocilizumab
50%
Randomized Controlled Trial
25%
Receptor
25%
Adverse Event
25%
Biological Product
25%
Pathophysiology
25%
Monoclonal Antibody
25%
Diseases
25%
Nursing and Health Professions
Rheumatoid Arthritis
100%
Interleukin 6
100%
Inflammatory Arthritis
100%
Tumor Necrosis Factor
50%
Tocilizumab
50%
Biological Product
25%
Adverse Event
25%
Receptor
25%
Monoclonal Antibody
25%
Pathophysiology
25%
Diseases
25%
Immunology and Microbiology
Inflammatory Arthritis
100%
Interleukin 6
100%
Cytokine
75%
Tocilizumab
50%
Tumor Necrosis Factor
25%
Biological Product
25%
Monoclonal Antibody
25%
Tumor Necrosis Factor Alpha
25%